Image source: © 2025 Krish Capital Pty. Ltd.

Highlights

  • CAMP4 to raise up to $100 million in gross proceeds through private placement.

  • Proceeds will support the SYNGAP1 program, working capital, and corporate purposes.

  • Leadership transitions include Doug Williams, Ph.D., appointed as Board Chair.

CAMP4 Therapeutics Corporation (Nasdaq:CAMP), a clinical-stage biopharmaceutical company focused on developing regulatory RNA-targeting therapeutics, announced that it has entered into definitive securities purchase agreements with institutional and accredited investors for up to $100 million in gross proceeds through a private placement.

The financing includes an initial $50 million upfront investment, with the remaining $50 million contingent upon the achievement of pre-specified milestones. These milestones include securing regulatory clearance to initiate a Phase 1/2 clinical trial for CMP-SYNGAP-01, the Company’s lead candidate targeting SYNGAP patients.

Details of the Financing

At the initial closing, CAMP4 issued 26,681,053 shares of common stock priced at $1.53 per share, along with 36,361 shares at $1.65 per share to directors, employees, and consultants. Additionally, 6,003,758 pre-funded warrants were sold in lieu of common stock at $1.5299 per warrant.

Upon meeting milestones, the Company will be eligible to issue up to an additional 32,721,172 shares of common stock or equivalent pre-funded warrants for a further $50 million in gross proceeds.

The financing is led by Coastlands Capital and includes participation from new and existing investors such as Janus Henderson Investors, Balyasny Asset Management, Vivo Capital, 5AM Ventures, Adage Capital Management LP, Trails Edge Capital Partners, and the SynGAP Research Fund. Leerink Partners is acting as the lead placement agent, with Piper Sandler & Co., Cantor Fitzgerald, and Wedbush & Co. serving as co-placement agents.

Use of Proceeds

CAMP4 stated that the net proceeds will be allocated to advance the preclinical and clinical development of the SYNGAP1 program, as well as to support working capital and general corporate activities. The Company’s SYNGAP1 program focuses on restoring healthy protein levels to treat patients with SYNGAP-related genetic conditions.

Board and Management Updates

Alongside the financing, CAMP4 announced changes to its Board of Directors and management team. Doug Williams, Ph.D., has been appointed as the new Board Chair, succeeding Steven Holtzman, who will continue as an Independent Director. Dr. Williams brings decades of leadership in drug development, having previously held senior roles at Biogen, Sana Biotechnology, and ZymoGenetics, among others.

The Company also elevated Daniel Tardiff, Ph.D., previously SVP and Head of Discovery, to Chief Scientific Officer, effective October 1, 2025. David Bumcrot, Ph.D., will transition to the role of Scientific Fellow, working closely with board member Murray Stewart, DM FRCP, who will chair the Research and Development committee.

Additionally, James Boylan, Ravi Thadhani, M.D., and Paula Ragan, Ph.D., have resigned from the Board of Directors.

Regulatory Note

The securities issued in this private placement are being sold in a transaction exempt from registration under the Securities Act of 1933. As such, they cannot be resold in the United States without either an effective registration statement or a valid exemption from registration. Investors have been granted customary resale registration rights for shares issuable upon exercise of the pre-funded warrants.